Martindale Pharma® Announces Extension of Licensing Agreement With Unimedic AB to Include Emergency Care Product Portfolio

WOOBURN GREEN, England, June 30, 2016 /PRNewswire/ --

- Extends Successful Partnership on Adrenaline Ampoules  

- Strengthens Partnership and Leverages Martindale Pharma Manufacturing Capabilities 

Martindale Pharma, the UK based leading international specialty pharma company today announced a new licensing agreement with its strategic partner Unimedic AB for its Emergency Care sterile ampoule products in Sweden, Denmark, Norway and Finland.

Under the new agreement, Unimedic AB will launch three undisclosed products. This builds on the long term relationship between the companies in Scandinavia which has seen Unimedic AB successfully commercialise a Martindale Pharma adrenaline ampoule product in Sweden. Financial terms of the agreement were not disclosed. The Companies will work together on regulatory and supply chain activities leading to the launch of the products.

Unimedic AB is the lead commercialisation partner in Scandinavia for Martindale Pharma. In addition to the Emergency Care portfolio, Unimedic AB is working with Martindale Pharma commercialising its opioid addiction portfolio in the region.

Michael Harris, Chief Executive Officer, commented: "Scandinavia is an area of focus for Martindale Pharma's international growth plans. We are pleased to extend our partnership with Unimedic AB, providing further opportunity to launch our products into additional markets. We intend to add additional products from our Emergency Care range to the licensing agreement we have with Unimedic in the next few months".

Notes to editors 

About Martindale Pharma^®  

Martindale Pharma is a leading UK-based, international specialty pharmaceutical company providing essential medicines to over 28 countries around the world.

Our strategy is to build leading positions in defined business segments where there is a high unmet medical need and a demand for improved product presentations. Our focus is on Opioid Addiction, Emergency Care, Hospital-initiated Medicines, Ophthalmics and Unlicensed Medicines (also called "Specials").

With a strong UK presence with expertise in marketing hospital and specialty medicines, Martindale Pharma is recognised as a strategic partner to the NHS and other healthcare providers and supplying over 100 licensed products and with a track record of successful new specialty product launches.

The business also includes a rapidly growing international organisation currently centred on three geographical regions: Saudi Arabia and the Gulf Co-Operation Council territory, Australia and South East Asia and Northern Europe (focused on Scandinavia).

Uniquely as an independent pharma company the company is underpinned by our own modern, efficient UK manufacturing facility which enables us to develop and compete globally to supply high quality, low cost specialty pharmaceuticals in sterile injection and oral liquid formats.

For further information visit our new website http://www.martindalepharma.co.uk

Media contacts:
Martindale Pharma        
Michael Clark    
Tel: +44 (0) 1628 551934    

Hume Brophy
Mary Clark, Hollie Vile, Elle Kress
Tel : +44 (0) 207 862 6390